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Fragile X syndrome is of rising maternal public health con-
cern. Fragile x syndrome is an inherited form of learning disa-
bility which was discovered in the late 1970s. It was discovered 
by cytogenetic detection of an associated fragile site on the X 
chromosome. Fragile x syndrome makes clinical diagnosis dif-
ficult as it is associated with subtle physical features and few 
medical problems. There is no known cure, and treatment plans 
consisting of behavioral interventions are the most effective for 
living with fragile x syndrome. Future better future treatment 
care plans, there needs to be in-depth research surrounding the 
social determinants of health fa1919ctors, which can affect a per-
son who has fragile x syndrome. As well as how having fragile x 
syndrome makes one more vulnerable to other chronic illnesses. 
Background:
Fragile X syndrome is one of the most commonly known 
inherited causes of intellectual disabilities. Both males and 
females who have fragile x syndrome exhibit a wide range of 
intellectual ability and may have various degrees of behavio-
ral, emotional, social, and learning difficulties. “In 1991, the 
gene responsible for FXS was identified on the X chromosome 
and named fragile x mental retardation 1 (FMR1 gene)” (3). 
By definition, Fragile X syndrome is a genetic disorder, which 
means there are changes to the genes in a person. Fragile X syn-
drome is caused by a change in the fragile x mental retardation 
1 (FMR1) gene. Fragile X syndrome and fragile x syndrome-
associated disorders are caused by a trinucleotide repeat (CGG) 
expansion mutation, which occurs in the promoter region (exon 
1) of FMR1. “Affected individuals with the full FXS mutation 
have > 200 repeats. When the full mutation is present, FMR1 
methylation occurs during gestation, which causes silencing 
of gene transcription” (3). “The FMR1 gene usually makes a 
protein called fragile x mental retardation protein (FMRP)” 
(3). Fragile x mental retardation protein (FMRP) is needed for 
there to be healthy brain development. People who have Fragile 
X syndrome are missing this necessary protein for proper brain 
development. Other people who have fragile x-associated disor-
ders have changes in their FMR1 gene but make some protein 
for brain development. Fragile X syndrome affects both females 
and males. It is seen that females have milder symptoms when 
compared to males. “The exact number of people who have 
FXS is unknown, but it has been estimated that about 1.4 per 
10,000 males and 0.9 per 10,000 females have FXS” (1). It affects 
almost twice as many males as it does females. However, it is 
shown that four times as many females appear to be carriers of 
the altered gene when compared to males. “1:250 females and 
1:1000 males)” (1). Most males who are diagnosed with fragile 
x syndrome have an intellectual disability. It is seen that a small 
number of males have less impaired function due to methyla-
tion patterns or mosaicism. “In females, FMRP levels depend 
on the X activation ratio or the percent of cells expressing the 
normal allele on the active X chromosome resulting in a range 
of normal intellectual ability to moderate intellectual disabil-
ity” (1). Fragile X Syndrome has also been found in many major 
ethnic groups and races. 
Scientists over the past two decades have made significant 
advancements in identifying and describing cellular, genetic, 
and molecular underpinnings of Fragile X Syndrome. These 
significant advancements help to make there be a more pre-
cise diagnosis of the condition. The current challenge at hand 
is to move from focusing on accurate diagnosis and make sure 
there is public health action in regards to Fragile X Syndrome. 
To ensure there is appropriate public health action taken it is 
required there be a better understanding of the natural history 
of Fragile X syndrome, clear description on how the complex 
conditions can affect the individual diagnosed and their families, 
and the identification of studied interventions and treatments 
which will lead to better health outcomes. Learning about the 
lifespan of those infected by Fragile X syndrome from a clinical 
aspect, family aspect, caretaker aspect, it will help as we design 
both treatments and services to provide the best optimal care. 
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 Signs & Symptoms
There are various signs to look out for to see if one may 
have Fragile X syndrome. Starting from a young child, one can 
start to notice if the child has developmental delays such as not 
walking, not sitting, or talking around the age of other chil-
dren the same age would. Another sign to look out for is learn-
ing disabilities and trouble learning new skills. Moreover, one 
can look for social and behavioral problems as well. These signs 
include the child not making eye contact, having trouble paying 
attention, having anxiety, acting and speaking without think-
ing, hand flapping, and being very active. “Fragile x syndrome 
is characterized by moderate intellectual disability in affected 
males and mild intellectual disability in affected females’’ (5). 
It is seen that males who have fragile x syndrome have some 
degree of intellectual disability, which can range from mild to 
severe. It is seen that females who have fragile x syndrome can 
have normal intelligence and some degree of intellectual dis-
ability. “The physical features in affected males are varied and 
may not be obvious until puberty” (5). An example of the physi-
cal features affected includes a large head, long face, protrud-
ing ears, prominent forehead, and chin, loose joints, low mus-
cle tone, flat feet, frequent ear infections, heart problems, and 
crossed eyes (strabismus). Autism spectrum disorders can also 
occur and is frequently seen in people with fragile x syndrome. 
The autistic behaviors which could be displayed include hand 
flapping, poor eye contact, or self-stimulating behaviors. Lastly, 
motor and language delays can be present and become more 
apparent over time.
Screening, Testing, and Diagnosis
There has been established population-based screening pro-
grams for several genetic conditions in newborn, preconception, 
and in prenatal settings. “Specific criteria, such as those devel-
oped by the World Health Organization, are available to pro-
vide guidance on which conditions are suitable for screening” 
(4). Early diagnosis starts when a child is young. The diagnosis 
of fragile x syndrome happens when the young child is approx-
imately three years old of age. The child should show signs of 
delayed or absent speech. Other signs and problems that can be 
recurrent in children before the age of 2 years include delayed 
motor milestones, hypotonia, poor eye contact, hand flapping, 
delayed motor milestones, frequent emesis, and irritability. “The 
behavior of boys with FXS typically includes attention deficit 
hyperactivity disorder (ADHD), with significant impulsivity 
and anxiety, as well as behaviors that include repetitive lan-
guage, hand biting, hand stereotypies, rocking, and sometimes 
headbanging” (8). Having these behaviors combined with lan-
guage and social deficits can lead to the diagnosis of an autism 
spectrum disorder (ASD) before the diagnosis of fragile x syn-
drome. “Approximately 30% of boys with FXS meet the diag-
nostic criteria for autism, and these children have the lowest 
developmental and adaptive behavior scores of those with FXS” 
(8). Children who are diagnosed with fragile x syndrome are fre-
quently described as being hyper-aroused, which is an imbalance 
of the excitatory and inhibitory synaptic pathways. Relatives to 
the child being diagnosed with fragile x syndrome may also be 
at risk of having children with intellectual disabilities, and it is 
advised they seek out genetic counseling. By conducting other 
clinical observations that may also reveal the FXS phenotype. 
“Sometimes a family history of ID, ASD, neurological problems 
(such as tremor, ataxia, or dementia in one of the grandparents), 
or early menopause (before 40 years of age) will lead the clini-
cian to diagnose FXS in the family” (8).
To test to diagnose if one has fragile x syndrome, DNA 
has to be taken by conducting a blood test. A doctor or genetic 
counselor can order the test. The testing can help to find if there 
are changes in the FMR1 gene, which can lead to the develop-
ment of fragile x associated disorders. Moreover, there may be a 
need for a late diagnosis in older patients. These older patients 
are those who may have undergone genetic testing before the 
1991 discovery of the FMR1 gene, or the patients may be show-
ing a mild form of the disease showing atypical symptoms. 
“Occasionally, individuals with fragile x syndrome were insti-
tutionalized in their adolescence or adulthood years, without a 
subsequent diagnostic study to find the cause of their intellec-
tual disability” (8). Reasons why proper screening and diagnos-
ing is urgently needed. 
To improve the screening policies and criteria, it would be 
effective to see if women early in pregnancy can be tested to see 
if they have the pre-mutation or full fragile X mutation. The 
diagnostic testing could then be followed out on fetal cells to 
help with identifying fetuses that transitioned to the full muta-
tion. “Prenatal screening would be restricted to pregnant women, 
because normal transmitting males do not give rise to offspring 
with the fragile X phenotype and because full mutation fragile 
x males rarely have children” (4). If a pre-mutation is identified 
in a woman, she will be offered DNA and amniocentesis test-
ing to determine the fragile X genotype of the fetal cells. There 
is no effective treatment for the mental retardation associated 
with fragile x syndrome, but prenatal screenings for the disorder 
allow the parents to have the option of selective termination of 
affected fetuses. This would be an act of secondary prevention. 
A diagnosis of fragile x syndrome can be of help to a fam-
ily as it will provide reasonings as to why their child is having 
intellectual disabilities and behavior problems. This allows the 
family and caregivers to learn more about fragile x syndrome 
and be able to help the child to reach his or her full potential. 
The results of the DNA tests can affect family members and 
raise issues, to help eliminate this; It is advised to consider hav-
ing genetic counseling before getting tested.
Treatment
Currently, there is no successful treatment available for 
fragile x syndrome. Treatment services can help those infected 
by fragile x syndrome learn essential skills. These services can 
include and are not limited to learning to walk, talk, and interact 
with others. For additional treatment, medicine can help as well. 
Medicine can be used to control some issues, such as behavior 
problems. For the best optimal treatment plan for people who 
have fragile x syndrome, parents, and healthcare providers have to 
work together in one accord and be involved through the treat-
ment plan and support one another. This team of support can 
also include teachers, childcare providers, coaches, therapists, and 
other members of the affected family. “The direct medical and 
social costs associated with the lifetime treatment and care of a 
mentally retarded person are estimated to be between one and 
four million dollars in the United States, depending on sever-
ity” (6). These costs may raise issues for those diagnosed with 
fragile x syndrome and their families. By taking advantage of 
all the available resources, it will be an aid in helping to make 
sure they have a successful treatment plan.
It is reported that reducing sensory and anxiety issues will 
help to reduce challenging behaviors that some children with 
fragile X syndrome have. It is suggested in several case studies that 
the use of behavioral principles such as positive reinforcement is 
effective. "Behavioral interventions can be effective for children 
with FXS through the development of individualized multicom-
ponent intervention plans implemented by parents and sup-
ported by professionals” (7). Moreover, few studies have exam-
ined educational or cognitive interventions for individuals who 
have fragile x syndrome. It was found that learning strategies 
that incorporate visually based experiential or holistic learning 
were most successful among young children who have fragile x 
syndrome. “A recent case study found a combination of early 
pharmacologic treatment combined with intensive educational 
interventions resulted in improved behavior and normal IQ in 
2 young children with FXS” (7). These intensive interventions 
include memory and cognitive games, which visualized math 
tasks and supplemental occupational therapy, social skills train-
ing, and speech-language therapy. “Pharmacotherapy is fre-
quently used as a primary intervention to target specific symp-
toms for individuals with FXS (7). For the neuropsychiatric 
symptoms of those diagnosed with fragile x syndrome, there 
are guidelines suggested for treatment that involve the use of 
stimulants or selective serotonin reuptake inhibitors, and they 
work to decrease hyperactivity, psychiatric symptoms, and cog-
nitive deficits. 
Another option for treatment includes early intervention 
services. Children from birth to 3 years old can benefit from 
early intervention services and learn essential skills. These ser-
vices are an aid in helping to improve a child’s development. A 
child does not have to be diagnosed with fragile x syndrome to 
be eligible for services. Each state has an early intervention sys-
tem in which children can seek enrollment to be provided with 
these services. Once in the early intervention system, the child 
is eligible to have an evaluation. If treatment is needed for lan-
guage delays, speech therapy is offered and often does not need a 
formal diagnosis to be obtained. Early intervention is an impor-
tant treatment option as well as treatment services at any age. 
Public Health Recommendations
The identification and treatment of fragile x syndrome are 
of high public health importance. The information presented 
provides an understanding of fragile x syndrome as well as its 
screening protocols and its lack of inefficient treatment options. 
There is a wealth of information and research did in regards 
to fragile x syndrome, but much work is needed to support 
affected individuals and families fully. There are areas in which 
we have current limited knowledge in regards to fragile x syn-
drome. These areas include the prevalence estimates for the full 
mutation lack precision, no large scale population-based study 
on fragile x syndrome available, and data is unknown about the 
sociodemographic characteristics of fragile x syndrome popula-
tions. Furthermore, there is not any adequate data in regards to 
fragile x syndrome variability among ethnic and racial groups. 
The medical problems and physical features associated with 
fragile x syndrome are already well documented. What is lack-
ing is the public health issues that are related to fragile x syn-
drome. These public health issues that have little research include 
details on health disparities, access to preventative care, health 
promotion activities, and healthcare decision making. The rate 
of communication of health information relevant to individuals 
affected by fragile x syndrome is also lacking. There is also lit-
tle data on the prevalence of noncommunicable diseases among 
individuals who have fragile x syndrome. Data is needed on the 
prevalence of noncommunicable diseases as well as how it com-
pares to other intellectual and developmental groups and also 
compared to the general population. “There is a shortage of evi-
dence regarding service use, intensity, or efficacy for school-age 
and preschool children with FXS, including special education 
eligibility and the types of educational services most commonly 
provided” (7). If we had the evidence, we could use the infor-
mation to develop more precisely targeted treatment options. 
It is currently very challenging to conduct high-quality inter-
vention studies that target specific behaviors since individuals 
with fragile x syndrome are located in broad ranges. For future 
intervention research, there needs to be more research done on 
the efficacy of treatment plans. Finally, the use of behavioral 
interventions and medications in the first year of life needs to 
be examined. As well as the efficacy of large scale screening such 
as newborn screening. With the results from the research, it will 
help public health professionals in the future push for resources 
to be taken by those affected early on with fragile x syndrome. 
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